COMPASS
A randomized controlled trial of rivaroxaban for the prevention of cardiovascular events in patients with coronary or peripheral artery disease
- Stadium
- klaar
- Middel
- rivaroxaban
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 1 januari 2013
- Last Patient In
- 9 mei 2016
- Last Patient Last Visit
- 28 februari 2018
National Lead
dr. A.M.W. Alings
Cardioloog
Studiedirecteur
